Meeting
2023 ASCO Annual Meeting
Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.
Authors
Subotheni Thavaneswaran
NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia
Subotheni Thavaneswaran , Antony Mersiades , Frank Po-Yen Lin , David Espinoza , John P. Grady , Chee Khoon Lee , Jayesh Desai , Michael Paul Brown , Peter S. Grimison , Kenneth John O'Byrne , Rosemary A. Harrup , Adnan Nagrial , Lucille Sebastian , Sarah Chinchen , Maya Kansara , Paul Stanley Craft , Michael Millward , John Simes , Anthony M. Joshua , David Morgan Thomas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Clinical Trial Registration Number
ACTRN12619001265167
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3127)
DOI
10.1200/JCO.2023.41.16_suppl.3127
Abstract #
3127
Poster Bd #
325
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
![An analysis of the prevalence of <I>HER2</I> and <I>KRAS</I> mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC).](https://d201v5jt9ylckg.cloudfront.net/132/8167/83454/83454_poster_pv.jpg)
An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC).
First Author: Tom Stinchcombe
Poster
2024 ASCO Annual Meeting
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.
First Author: Melissa Lynne Johnson
Poster
2023 ASCO Annual Meeting
Real-world analysis of commercially insured and Medicare Advantage patients with advanced cancer and rates of molecular testing.
First Author: Stacey DaCosta Byfield
Poster
2023 ASCO Annual Meeting
Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.
First Author: Subotheni Thavaneswaran